


Lasmiditan hemisuccinate

05/20

ALTERNATE NAMES: Lasmiditan succinate; butanedioic acid, 2,4,6-trifluoro-N-[6-(1-methylpiperidine-4-carbonyl)pyridin-2-yl]benzamide; 2,4,6-Trifluoro-N-(6-((1-methylpiperidine-4-yl)carbonyl)pyridin-2-yl)benzamide hemisuccinate; Butanedioic acid, compd. with 2,4,6-trifluoro-N-(6-((1-methyl-4-piperidinyl)carbonyl)-2-pyridinyl)benzamide (1:2); COL-144; LY573144

CATALOG #: B3032-5 5 mg
B3032-25 25 mg

STRUCTURE:



MOLECULAR FORMULA: C₄₂H₄₂F₆N₆O₈

MOLECULAR WEIGHT: 872.8

CAS NUMBER: 439239-92-6

APPEARANCE: Solid

PURITY: ≥98%

SOLUBILITY: ~9 mg/ml in ethanol
~14 mg/ml in water
~100 mg/ml in DMSO

DESCRIPTION: Lasmiditan hemisuccinate is a highly selective serotonin 5-HT_{1F} receptor agonist. It shows high-affinity for 5-HT_{1F} receptor with a K_i value of 2.21 nM *in vitro*. Oral administration of lasmiditan (3 mg/kg) inhibited markers associated with electrical stimulation of the trigeminal ganglion in rodent models of migraine. It is approved for the acute treatment of migraine with or without aura in adults.

STORAGE TEMPERATURE: -20°C. Protect from air. Store under desiccating conditions.

HANDLING: Do not take internally. Wear gloves and mask when handling the product! Avoid contact by all modes of exposure.

REFERENCES:

- Nelson, D.L., Phebus, L.A., Johnson, K. W., et al. Preclinical Pharmacological Profile of the Selective 5-HT_{1F} Receptor Agonist Lasmiditan. 30(10):1159-69 (2010).
- Lamb, Y.N. Lasmiditan: First Approval. Drugs. 79(18):1989-1996 (2019).

RELATED PRODUCTS:

Olanzapine (Cat. No. B2677)
Pimavanserin Tartrate (Cat. No. B1915)
Bifeprunox (Cat. No. B2921)
Bromocriptine (mesylate) (Cat. No. 2916)
LY-310762 hydrochloride (Cat. No. B2190)

DISCLAIMER: **FOR RESEARCH USE ONLY! Not to be used on humans.**